March 22 (Reuters) - Marinus Pharmaceuticals Inc :
* MARINUS PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR GANAXOLONE IN THE TREATMENT OF LENNOX-GASTAUT SYNDROME
* MARINUS PHARMACEUTICALS INC - EXPECTS TO INITIATE A MULTIPLE ASCENDING DOSE STUDY OF A SECOND GENERATION GANAXOLONE FORMULATION IN Q2 OF 2023
* MARINUS PHARMACEUTICALS INC - PLANNING TO FINALIZE CLINICAL PROGRAM DESIGN FOR LGS IN SECOND HALF OF THIS YEAR Source text for Eikon: Further company coverage:
The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
_05_29_2023_03_34_34_945588.jpg)
